Literature DB >> 19408575

Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.

Chaiwat Prawettongsopon1, Sariya Asawakarn, Tuangporn Suthiphongchai.   

Abstract

Upregulation of the PI3K pathway has often been reported in androgen-independent prostate cancer and is implicated in cancer cell survival and proliferation in the absence of androgen. Inhibition of PI3K by LY294002 suppressed cell invasion and motility of the highly metastatic androgen-independent Dunning rat prostate cancer MLL cell line with similar IC50 values and inhibition profile. Moreover, LY294002 attenuated expression of urokinase plasminogen activator (uPA) without any significant effect on that of matrix metalloproteinase 2. These results indicated that the role of PI3K in MLL cell invasion is by regulating cell motility and uPA expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408575     DOI: 10.3727/096504009787721195

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  3 in total

1.  Gambogic acid inhibits TNF-α-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-κB signaling pathways.

Authors:  Lei Lü; Dong Tang; Liang Wang; Lu-qi Huang; Guo-song Jiang; Xing-yuan Xiao; Fu-qing Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

2.  TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.

Authors:  Yohei Sekino; Xiangrui Han; Takafumi Kawaguchi; Takashi Babasaki; Keisuke Goto; Shogo Inoue; Tetsutaro Hayashi; Jun Teishima; Masaki Shiota; Wataru Yasui; Akio Matsubara
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

3.  Positive Association of Leptin and Artery Calcification of Lower Extremity in Patients With Type 2 Diabetes Mellitus: A Pilot Study.

Authors:  SanBao Chai; Yao Chen; SiXu Xin; Ning Yuan; YuFang Liu; JianBin Sun; XiangYu Meng; YongFen Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.